Veristat Taps Accomplished Industry Leaders to Support Growth and Innovation
Veristat Welcomes Three New Leaders to Executive Team, Driving Global Growth and Regulatory Success in Clinical Research
Veristat Congratulates HIPRA for EMA Approval of Its BIMERVAX® COVID-19 Vaccine
Veristat Delivered a Full Range of Clinical Trial Services Culminating in Marketing Authorization of HIPRA’s SARS-CoV-2 Vaccine and...
Veristat Supported Eight Regulatory Approvals in 2022, the Majority for Therapies Designed...
Supporting Its Continued Commitment During Rare Disease Month to Making a Difference in the Lives of Patients Faced with Limited Treatment...
Veristat Presents Integrated, Customized DCT Solutions at the DTRA Annual Meeting
Highlights the unique advantages its DCT solutions hold for small to mid-size biotechs conducting trials for complex diseases
Veristat Joins Decentralized Trials & Research Alliance (DTRA) to Improve the Patient...
Advances commitment to support patient needs across diverse populations
Veristat is Recognized on the 2022 Inc. 5000 List of America’s Fastest-Growing Private...
Veristat’s Bold Thinking and World Class Clinical, Regulatory and Commercialization Capabilities Allow the Company to Successfully Tackle...
Veristat congratulates Awakn - UK State Funding to Identify Optimal Pathway to Market In UK...
Veristat congratulates Awakn for being awarded UK State Funding to Identify Optimal Pathway to Market In UK & US For Its Lead Clinical...
Cindy Henderson Named Veristat Chief Commercial Officer
Instrumental to Veristat’s growth, success, and client satisfaction over the last 15 years
Veristat Launches Strategic Resourcing to Build Greater Flexibility in its Suite of...
Providing sponsors expert staff to accelerate milestones and support study success